Tasigna Approval May Be Again Delayed To Allow FDA Advisory Cmte. Review – Novartis
This article was originally published in The Pink Sheet Daily
Executive Summary
NDA for next-generation chronic myeloid leukemia therapy currently has late October action date, but FDA may convene ODAC to review Tasigna in December.
You may also be interested in...
Novartis’ Tasigna Approved By FDA For CML Patients Resistant to Gleevec
The Bcr-Ab1 inhibitor will be available in the U.S. “within days,” the company says.
Novartis’ Tasigna Approved By FDA For CML Patients Resistant to Gleevec
The Bcr-Ab1 inhibitor will be available in the U.S. “within days,” the company says.
No Big Surprise For Novartis: Prexige Is “Not Approvable” At FDA
Firm now plans to discuss path forward, which may include additional trials of the COX-2 inhibitor, with FDA, Novartis tells "The Pink Sheet" DAILY.